Gilead Sciences to Present at Upcoming Investor Conferences
Get Alerts GILD Hot Sheet
Join SI Premium – FREE
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
BofA Securities Health Care Conference on Tuesday, May 9 at 2:20pm ET
RBC Capital Markets Global Healthcare Conference on Tuesday, May 16 at 11:00am ET
Goldman Sachs Global Healthcare Conference on Monday, June 12 at 1:40pm ET
The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005622/en/
Jacquie Ross, CFA – Investors
[email protected]
Source: Gilead Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC
- Scaling “Total Wealth” Advice: An Interview with Libretto Founder Jeffery Coyle
- BNB Price Prediction Rips 15% in One Week and the Smartest Wallets Are Already Inside Pepeto
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Goldman Sachs, RBC Capital, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share